About
CardioVia is a medical device company developing a system called ViaOne. ViaOne allows minimally invasive access to the outer surface of the heart (the pericardial space), which has been recognized as a promising entry route to treat prevalent cardiovascular diseases such as tamponade, effusion, and arrhythmias. ViaOne is intended to ensure safe pericardial access in order to avoid complications and ensure procedural success. It aims to increase the physicians confidence during the procedure while providing safety and assurance to the patient. The companys technology ensures that no needle is exposed to the heart at any time. The procedure is performed in a controlled and measured manner while synchronizing with the heartbeats, and the system allows penetration to the outer surface of the pericardial space without risk of puncturing the heart muscle. CardioVia established a complete operating system in preclinical studies and is currently in the process of receiving regulatory approvals from the FDA and CE. In addition, the project has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement number 868213.
Funding history · 1 round · $55K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is CardioVia's primary product?
- CardioVia's primary product is ViaOne, a system designed for minimally invasive access to the outer surface of the heart (pericardial space).
- When was CardioVia founded?
- CardioVia was founded in December 2017.
- What significant regulatory approval did CardioVia receive in April 2025?
- In April 2025, CardioVia announced that it received U.S. Food and Drug Administration (FDA) clearance for its ViaOne system.
- Has CardioVia received any grants?
- Yes, in August 2019, CardioVia received a grant of $55,000 from the IIA (Israel Innovation Authority).
- What type of funding has CardioVia received from the European Union?
- CardioVia received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 868213.
- What is CardioVia's current employee count?
- CardioVia currently has 8 employees.
- Which investor participated in CardioVia's Seed round?
- NGT3 participated in CardioVia's Seed funding round in September 2018.
- What is the purpose of CardioVia's ViaOne system?
- The ViaOne system is intended to ensure safe pericardial access, avoid complications, and ensure procedural success for treating cardiovascular diseases such as tamponade, effusion, and arrhythmias.
- What is CardioVia's legal name and any former names?
- CardioVia's legal name is not specified, but it was formerly known as Cardio Safex.